Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BRIACELL THERAP (BCTX : NSDQ)
 
 • Company Description   
BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.47 Daily Weekly Monthly
20 Day Moving Average: 439,842 shares
Shares Outstanding: 15.28 (millions)
Market Capitalization: $68.30 (millions)
Beta: 1.13
52 Week High: $12.47
52 Week Low: $2.82
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -41.57% -35.97%
12 Week -43.70% -38.92%
Year To Date -46.01% -35.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3RD FLOOR BELLEVUE CENTRE 235-15TH STR
-
WEST VANCOUVER,A1 V7T 2X1
CAN
ph: 604-921-1810
fax: 604-921-1898
None http://www.briacell.com
 
 • General Corporate Information   
Officers
William V. Williams - President and Chief Executive Officer
Gadi Levin - Chief Financial Officer
Charles Louis Wiseman - Founder; Principal Advisor & Member of Scientific
Farrah Dean - Mang. of Corp. Devel.
Farrah Dean - Mang. of Corp. Devel.

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 10778Y302
SIC: 2834
Fiscal Year
Fiscal Year End: July
Last Reported Quarter: 01/01/22
Next Expected EPS Date: 07/05/22
Share - Related Items
Shares Outstanding: 15.28
Most Recent Split Date: 1.00 (0.00:1)
Beta: 1.13
Market Capitalization: $68.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.49
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 41.46%
vs. Previous Quarter: -60.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
04/30/22 - -
01/31/22 - -30.65
10/31/21 - -31.70
ROA
04/30/22 - -
01/31/22 - -29.07
10/31/21 - -28.73
Current Ratio
04/30/22 - -
01/31/22 - 79.86
10/31/21 - 129.74
Quick Ratio
04/30/22 - -
01/31/22 - 79.86
10/31/21 - 129.74
Operating Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Net Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Pre-Tax Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Book Value
04/30/22 - -
01/31/22 - 2.99
10/31/21 - 3.57
Inventory Turnover
04/30/22 - -
01/31/22 - -
10/31/21 - -
Debt-to-Equity
04/30/22 - -
01/31/22 - 0.00
10/31/21 - 0.00
Debt-to-Capital
04/30/22 - -
01/31/22 - 0.00
10/31/21 - 0.00
 

Powered by Zacks Investment Research ©